Recursion Pharmaceuticals, Inc. RXRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s retained earnings?
- Recursion Pharmaceuticals, Inc. (RXRX) reported retained earnings of -$2.19B in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s retained earnings decreased by 34.3% year-over-year, from -$1.63B to -$2.19B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s retained earnings has grown at a 57.6% compound annual growth rate (CAGR), from -$213.6M to -$2.08B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.